Your browser version may not work well with NCBI's Web applications. More information here...
1: Nat Med. 2005 Apr;11(4):446-9. Epub 2005 Mar 27.
Related Articles, Links
Click here to read Click here to read Click here to read
Comment in:
A chimeric human-cat fusion protein blocks cat-induced allergy.

Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A.

The Hart and Louise Lyon Laboratory, Division of Clinical Immunology/Allergy, Department of Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, California 90095-1680, USA. dczhu@ucla.edu

Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a chimeric human-cat fusion protein composed of a truncated human IgG Fcgamma1 and the major cat allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fcgamma-Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. Such inhibition was associated with altered Syk and ERK signaling. The Fcgamma-Fel d1 protein also blocked in vivo reactivity in FcepsilonRIalpha transgenic mice passively sensitized with human IgE antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fcgamma-Fel d1 protein alone did not induce mediator release. Chimeric human Fcgamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.

Publication Types:
PMID: 15793580 [PubMed - indexed for MEDLINE]

PMCID: PMC1866216